ACA
OTLK icon

Avoro Capital Advisors’s Outlook Therapeutics OTLK Stock Holding History

Avoro Capital Advisors’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-4,250
Closed -$630K – 38
2019
Q1 		$630K Hold
4,250
– – 0.03% 32
2018
Q4 		$340K Sell
4,250
-22
-0.5% -$2.71K 0.02% 34
2018
Q3 		$670K Hold
4,272
– – 0.03% 43
2018
Q2 		$578K Hold
4,272
– – 0.02% 41
2018
Q1 		$608K Hold
4,272
– – 0.03% 51
2017
Q4 		$889K Hold
4,272
– – 0.06% 44
2017
Q3 		$936K Hold
4,272
– – 0.07% 39
2017
Q2 		$684K Hold
4,272
– – 0.09% 40
2017
Q1 		$1.83M Hold
4,272
– – 0.23% 37
2016
Q4 		$2.06M Buy
4,272
+1,454
+52% +$814K 0.42% 31
2016
Q3 		$1.92M Sell
2,818
-99
-3% -$62.9K 0.34% 35
2016
Q2 		$1.59M Buy
+2,917
New +$1.74M 0.35% 31

Other funds holding OTLK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LA
LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RIA
Realta Investment Advisors Wilmington, Delaware $322M AUM 39.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Avoro Capital Advisors's OTLK Position: Q2 2019 in Review

Avoro Capital Advisors sold out of Outlook Therapeutics (OTLK) in Q2 2019, closing a stake of 4,250 shares — an estimated $630K sold.

Avoro Capital Advisors first reported a position in OTLK in Q2 2016 and held it in 12 quarters. The position peaked at $2.06M in Q4 2016. 14 funds tracked by Wall St. Rank hold OTLK as of Q2 2019.

  • Avoro Capital Advisors reported no remaining Outlook Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Avoro Capital Advisors sold 4,250 Outlook Therapeutics shares in Q2 2019, an estimated $630K.
  • Avoro Capital Advisors first reported a position in Outlook Therapeutics in Q2 2016 and held it in 12 quarters.
  • Avoro Capital Advisors's Outlook Therapeutics position peaked at $2.06M in Q4 2016.
  • 14 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2019.

Based on Avoro Capital Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.